JENA, Germany — InflaRx N.V. (Nasdaq: IFRX), a frontrunner in the development of anti-inflammatory therapeutics targeting the complement system, has secured a prestigious late-breaking poster session at the American Society of Nephrology’s (ASN) Kidney Week 2026. The conference, which serves as a global hub for renal research and clinical innovation, is scheduled to take place in Denver, Colorado, from October 21 to 25.
The company will present new findings centered on its flagship oral candidate, izicopan, in a session titled “Late-Breaking Research Posters [LB-PO]” on the morning of October 22. The presentation, titled “Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antagonist, Demonstrates Promising Therapeutic Potential in Kidney Disease Models,” is expected to bolster the company’s push into the treatment of ANCA-associated vasculitis (AAV) and other complex renal indications.
Izicopan is a small molecule inhibitor designed to block the C5a receptor, a critical driver in inflammatory pathways. According to data released ahead of the conference, the drug offers a distinct competitive advantage over currently marketed inhibitors. Notably, in vitro studies have shown that izicopan avoids the time-dependent inhibition of cytochrome P450 3A4 (CYP3A4), a liver enzyme responsible for metabolizing many essential drugs, including glucocorticoids. By circumventing this interaction, izicopan minimizes the risk of harmful drug-drug interactions that often complicate care for patients with chronic autoimmune conditions.
The safety and efficacy profile of the drug has been a central theme in InflaRx’s recent clinical narrative. First-in-human studies demonstrated that the molecule was well-tolerated across a wide dosage range, from 3 mg to 240 mg, with no significant safety signals identified. Furthermore, pharmacodynamic testing revealed that the drug achieves a consistent ≥90% blockade of C5a-induced neutrophil activation, suggesting a best-in-class potential for the treatment of inflammatory flare-ups.
Beyond the renal sector, InflaRx has seen positive results for izicopan in other immunological trials. In Phase 2a data, patients suffering from hidradenitis suppurativa experienced rapid, meaningful reductions in abscesses and pain scores, with effects that deepened even after the cessation of therapy. Similarly, in patients with chronic spontaneous urticaria, the drug showed significant success in lowering the Urticaria Activity Score (UAS7).
“Our focus remains on leveraging our proprietary anti-C5a and anti-C5aR technologies to address the most challenging inflammatory diseases,” said a company representative. As the company moves toward broader renal development, the upcoming presentation in Denver is widely viewed as a pivotal moment for InflaRx to validate the clinical utility of izicopan in the high-stakes nephrology market.
InflaRx, founded in 2007, continues to operate out of its headquarters in Jena, Germany, with an expanding footprint in Munich and Ann Arbor, Michigan. The company remains in a period of active clinical development, building on the success of both its novel oral inhibitor, izicopan, and its intravenously delivered monoclonal antibody, vilobelimab.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
